BridgeBio Pharma, Inc.
BBIO
Pozycja w akcjach
#1610
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Cena akcji
$68.06
Kapitalizacja rynkowa
$13.31B
Zmiana (1 dzień)
2.52%
Zmiana (1 rok)
23.93%
Kraj
US
Handel BridgeBio Pharma, Inc. (BBIO)
Kategoria
Healthcare
Zyski dla BridgeBio Pharma, Inc. (BBIO)
Zyski w Jun 2026 TTM: $-706.17M
Według najnowszych raportów finansowych BridgeBio Pharma, Inc., obecny zysk firmy wynosi $-706.17M. W roku 2023 firma osiągnęła zysk w wysokości $-653.25M, spadek w porównaniu do zysku z roku 2022, który wynosił $-484.65M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy BridgeBio Pharma, Inc. od 2017 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-706.17M | 30.24% |
| 2024 | $-542.19M | -17.00% |
| 2023 | $-653.25M | 34.79% |
| 2022 | $-484.65M | -17.36% |
| 2021 | $-586.45M | 16.02% |
| 2020 | $-505.49M | 75.16% |
| 2019 | $-288.59M | 70.31% |
| 2018 | $-169.45M | 286.59% |
| 2017 | $-43.83M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -846.98% |
US
|
|
| $-3.09B | 337.15% |
US
|
|
| $-4.02B | 468.73% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -376.23% |
NL
|
